‘Ideal’ German Antibodies have promising data for Gastro Cancer

17/05/2016 - 2 minutes

Ganymed is presenting promising results of its phase II trial in gastroesophageal cancer at the ASCO Annual meeting 2016 in Chicago, one of the leading Oncology conferences worldwide. 

ganymed_cancer_imab_ideal_antibodyBased in Mainz (Germany), Ganymed is a Biopharma developing immunotherapies to tackle cancer, having joined forces with BioNTech (Germany’s larget private Biotech) 2 years ago to create one of the largest research centres in the country.

Ganymed is developing a new class of immunotherapies dubbed ideal monoclonal antibodies (IMABs). This technology aims to do something similar to Nanobiotixlocalised radiotherapy – but instead to work for anticancer antibodies.

IMABs are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This tumor specificity means that anticancer potency can be increased, without a corresponding increase in toxicity.

Now, Ganymed is presenting results for a Phase II trial (FAST), which enrolled 210 patients with adenocarcinoma of the stomach,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!